ImmuCell Corporation
ICCC
Positions held
Your positionsICCC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $88.55M | Enterprise value | $92.14M | Trailing P/E | 139.29 | Forward P/E | -88.64 |
| PEG | — | Price / book | 2.82 | Beta | 0.57 | Dividend yield | 0.00% |
| Revenue growth | 11.5% | Earnings growth | 259.9% | Gross margin | 40.3% | Operating margin | 26.9% |
| Profit margin | 2.6% | ROE | 2.6% | ROA | 6.2% | Debt / equity | 0.40 |
| Current ratio | 4.75 | Free cash flow | $3.08M | Analyst recommendation | none | Mean target | — |
| 52w high | $12.10 | 52w low | $4.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2M | $10.4M | $7.6M | $5.5M | $6.4M | — |
| Op margin | 26.9% | 19.0% | -0.8% | 0.4% | 8.8% | — |
| Net income | $1.8M | $1.9M | -$2.8M | -$0.1M | $0.5M | — |
| Gross margin | 33.9% | 45.0% | 38.2% | 42.9% | 43.7% | — |
| Gross profit | $2.4M | $4.7M | $2.9M | $2.4M | $2.8M | — |
| Operating income | $1.9M | $2.0M | -$0.1M | $0.0M | $0.6M | — |
- Revenue -31% vs prior quarter ($7.2M vs $10M).
- Gross margin 33.9% (was 45% prior quarter).
- Operating margin expanded to 26.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M |
| Op margin | 6.0% | -6.2% | -32.9% | -12.4% |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M |
| Gross margin | 41.4% | 30.0% | 22.1% | 41.2% |
| Gross profit | $11.4M | $7.9M | $3.9M | $7.6M |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
2026-09-28 · Top Research Reports for Alphabet, Mastercard & AbbVie
2026-08-27 · ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
2026-08-20 · ImmuCell (ICCC) Q2 2026 Earnings Call Transcript
2026-08-14 · ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ...
2026-08-14 · ImmuCell Q2 Earnings Call Highlights
2026-08-14 · ImmuCell Corporation Q2 2026 Earnings Call Summary
2026-08-13 · ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
2026-08-06 · ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
Price (daily)
Full chart · RSI · MACD · patterns